<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126525</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-023</org_study_id>
    <nct_id>NCT04126525</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer</brief_title>
  <acronym>NeoATP</acronym>
  <official_title>NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-positive Locally Advanced Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant
      pyrotinib in early breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>1-2 weeks after surgery</time_frame>
    <description>pathological complete response</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>neoadjuvant pyrotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m^2, d1, 8, 15, 22 cisplatin 25mg/m^2, d1, 8, 15 every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>dual HER2 blockade in the neoadjuvant setting</description>
    <arm_group_label>neoadjuvant pyrotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, Aged ≥18 and ≤70 years

          -  Histologically confirmed invasive HER2 positive breast cancer, early disease(Stage
             ⅡA-Ⅲ)

          -  Subjects with at least one evaluable lesion

          -  ECOG 0-1

          -  Adequate organ function

        Exclusion Criteria:

          -  Metastatic disease (Stage IV)

          -  Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal
             absorption

          -  Treated or treating with T-DM1, lapatinib and neratinib before study entry

          -  History of immunodeficiency, including HIV-positive, suffering from other acquired,
             congenital immunodeficiency disease, or history of organ transplantation

          -  Subjects had any heart disease, including: (1) angina; (2) requiring medication or
             clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5)
             Any heart diseases judged by investigator as unsuitable to participate in the trial

          -  Female patients who are pregnancy, lactation or women who are of childbearing
             potential tested positive in baseline pregnancy test. Female patients of childbearing
             age that are reluctant to take effective contraceptive measures throughout the trial
             period

          -  Evidence of significant medical illness that in the investigator's judgment will
             substantially increase the risk associated with the subject's participation in and
             completion of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenjin Yin</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenjin Yin</last_name>
    <phone>86(21)68385569</phone>
    <email>followroad@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjin Yin</last_name>
      <phone>86(21)68385569</phone>
      <email>followroad@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 6, 2019</study_first_submitted>
  <study_first_submitted_qc>October 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 12, 2019</last_update_submitted>
  <last_update_submitted_qc>October 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Jinsong Lu</investigator_full_name>
    <investigator_title>Chief of Breast Surgery Department</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant</keyword>
  <keyword>pyrotinib</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

